D W Raisch
- Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependenceDennis W Raisch
Veterans Affairs Cooperative Studies Program, Clinical Research Pharmacy Coordinating Center, Albuquerque, NM 87106, USA
J Am Pharm Assoc (2003) 45:23-32. 2005..To assess the perceptions and attitudes of pharmacists and pharmacy technicians involved in an office-based opioid dependence treatment program using buprenorphine/naloxone...
- Understanding quality-adjusted life years and their application to pharmacoeconomic researchD W Raisch
Veterans Affairs Cooperative Studies Program, Clinical Research Pharmacy Coordinating Center, College of Pharmacy, University of New Mexico, Albuquerque 87106, USA
Ann Pharmacother 34:906-14. 2000....
- Variability in the assessment of adverse events in a multicenter clinical trialD W Raisch
Department of Veterans Affairs Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, College of Pharmacy, University of New Mexico, Albuquerque 87106, USA
Clin Ther 23:2011-20. 2001..Consistent documentation, characterization, and evaluation of adverse events (AEs) are needed during multicenter clinical trials to ensure accuracy of data reported to the US Food and Drug Administration and in the medical literature...
- Computerized system for outcomes-based antiemetic therapy in childrenM T Holdsworth
College of Pharmacy, University of New Mexico, Albuquerque 87131, USA
Ann Pharmacother 34:1101-8. 2000..To introduce a computerized data collection system used for an outcomes-based approach to antiemetic therapy in children, and to present data collected with this system in support of a new antiemetic dosing regimen...
- GI risk factors and use of GI protective agents among patients receiving nonsteroidal antiinflammatory drugsCrystal L Harris
Pharmaceutical Management and Research, Veterans Affairs Cooperative Studies Program Clinical Research Pharmacy, Albuquerque, NM 87106 4180, USA
Ann Pharmacother 40:1924-31. 2006..Patients at risk may not be prescribed protective therapies that might mitigate their risk of NSAID-associated GI complications...
- Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program SubstudySteven N Singh
Department of Veterans Affairs Medical Center, Washington, DC 20422, USA
J Am Coll Cardiol 48:721-30. 2006..The purpose of this study was to determine quality of life (QOL) and exercise performance (EP) in patients with persistent atrial fibrillation (AF) converted to sinus rhythm (SR) compared with those remaining in or reverting to AF...
- Amiodarone versus sotalol for atrial fibrillationBramah N Singh
Department of Veterans Affairs Medical Center, West Los Angeles, Calif 90073, USA
N Engl J Med 352:1861-72. 2005..The optimal pharmacologic means to restore and maintain sinus rhythm in patients with atrial fibrillation remains controversial...
- The role of the pharmacy coordinating center in the DIG trialCarol L Fye
Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, VA Medical Center, Albuquerque, New Mexico 87106 4180, USA
Control Clin Trials 24:289S-297S. 2003..As a direct result of involvement in the DIG trial, the PCC identified the need for an increased emphasis on computerization and automated support of clinical trials, especially LSTs...
- A comparison of veteran and nonveteran motivations and reasons for participating in clinical trialsHeather M Campbell
University of New Mexico College of Pharmacy, 2502 Marble, Albuquerque, NM 87131 0001, USA
Mil Med 172:27-30. 2007..Study delays often occur due to lack of recruitment. This study's primary objective was to compare veteran and nonveteran motivations and reasons...
- Promoting good clinical practices in the conduct of clinical trials: experiences in the Department of Veterans Affairs Cooperative Studies ProgramMike R Sather
VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Research and Development, Albuquerque, New Mexico, USA
Control Clin Trials 24:570-84. 2003....
- Pharmacoeconomic analysis of angiotensin-converting enzyme inhibitors in type 2 diabetes: a Markov modelHeather M Campbell
Veterans Affairs Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM 87106, USA
Ann Pharmacother 41:1101-10. 2007..Prevention of cardiovascular disease (CVD) events by initiating an angiotensin-converting enzyme (ACE) inhibitor on diagnosis of type 2 diabetes may increase survival and decrease costs...
- Opioid dependence treatment, including buprenorphine/naloxoneDennis W Raisch
Veterans Affairs Cooperative Studies Program, Clinical Research Pharmacy Coordinating Center, 2401 Centre, SE, Albuquerque, NM 87106 4180, USA
Ann Pharmacother 36:312-21. 2002..To review opioid dependence (OD) and its treatment. Pharmacologic treatments, including the use of buprenorphine/naloxone, are presented. Pharmaceutical care functions for outpatient OD treatment are discussed...
- Systematic review of piperacillin-induced neutropeniaMarc H Scheetz
Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL 60611, USA
Drug Saf 30:295-306. 2007..Report of neutropenia associated with piperacillin usage prior to 15 days of therapy is a novel finding that requires further evaluation. Current reporting methods poorly characterise patient groups at risk...
- Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR ProjectCharles L Bennett
VA Center for Management of Complex Chronic Care at Jesse Brown VA Medical Center, Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
J Am Coll Cardiol 50:1138-43. 2007..We sought to describe clinical and laboratory findings for a large cohort of patients with thienopyridine-associated thrombotic thrombocytopenic purpura (TTP)...
- Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturersCharles L Bennett
Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Arch Intern Med 167:1041-9. 2007..We compare safety efforts for evaluating serious ADRs conducted by the FDA and pharmaceutical manufacturers vs the RADAR project...
- Assessment of the impact of a patient clinical trials handbook among pharmacy studentsA Christie Graham
University of Wyoming School of Pharmacy, Laramie, Wyoming, USA
Clin Ther 27:238-45. 2005..It has been suggested that patients' knowledge and attitudes are improved by being given general written information about clinical trials...
- Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports projectLisa A Ladewski
Veterans Affairs Midwest Center for Health and Policy Research, Lakeside Division, Northwestern University Medical Center, Chicago, IL 60611, USA
J Clin Oncol 21:3859-66. 2003..To describe the clinical findings, occurrence rates, causality evidence, and dissemination media for serious cancer drug-associated adverse drug reactions (ADRs) reported in the postmarketing setting...
- Pharmacoeconomic implications of large multicenter clinical trialsDennis W Raisch
Ann Pharmacother 37:447-50. 2003
- Impact of pharmacists' directive guidance behaviors on patient satisfactionPuneet K Singhal
Pharmaceutical Health Services Research Program, School of Pharmacy, University of Maryland Baltimore, USA
J Am Pharm Assoc (Wash) 42:407-12. 2002..DG behaviors are social support behaviors and include such activities as supplying information about medications and providing encouragement and feedback regarding drug therapy...
- Impact of a clinical trials information handbook on patient knowledge, perceptions, and likelihood of participationHeather M Campbell
Veterans Affairs Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, University of New Mexico College of Pharmacy, Albuquerque, NM, USA
IRB 30:6-14. 2008